{"nctId":"NCT00727857","briefTitle":"Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.","startDateStruct":{"date":"2007-06"},"conditions":["Diabetes Mellitus"],"count":600,"armGroups":[{"label":"Pioglitazone 15 mg /Metformin 850 mg BID","type":"EXPERIMENTAL","interventionNames":["Drug: Pioglitazone and metformin"]},{"label":"Pioglitazone 15 mg BID","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Pioglitazone"]},{"label":"Metformin 850 mg BID","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Metformin"]}],"interventions":[{"name":"Pioglitazone and metformin","otherNames":["ACTOPLUS MET"]},{"name":"Pioglitazone","otherNames":["ACTOSÂ®","AD4833"]},{"name":"Metformin","otherNames":["Fortamet","Glucophage","Glucophage XR","Glumetza","Riomet"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria\n\n* Has type 2 diabetes.\n* Has received no treatment with antidiabetic medication in the 12 weeks prior to Screening, other than short-term use defined as less than or equal to 15 days.\n* A glycosylated hemoglobin greater than or equal to 7.5% and less than or equal to 10.0% at Screening.\n* Body mass index less than or equal to 45 kg/m2.\n* Has received counseling on lifestyle modification for type 2 diabetes, including diet and exercise.\n* Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.\n* Stable condition as determined by a physician.\n\nExclusion Criteria\n\n* Type 1 diabetes.\n* Unstable angina or heart failure of any etiology with New York Heart Association functional class III or IV.\n* History of myocardial infarction, cerebrovascular accident, percutaneous coronary intervention, coronary artery bypass graft, or transient ischemic attack in the 6 months prior to Screening.\n* Male participant has a serum creatinine level greater than or equal to 1.5 mg per dL or female subject has a serum creatinine level greater than or equal to 1.4 mg per dL.\n* Has a triglyceride level greater than 500 mg per dL.\n* Male participant has a hemoglobin level less than 10.5 g per dL or female subject has a hemoglobin level less than 10.0 g per dL.\n* Alanine aminotransferase level of greater than 2.5 times the upper limit of normal, active liver disease, or jaundice.\n* History of drug abuse (defined as any illicit drug use) or a history of alcohol abuse (defined as regular or daily consumption of more than 2 alcoholic drinks per day) within 2 years prior to Screening.\n* Has been discontinued from a thiazolidinedione or metformin therapy due to lack of efficacy or clinical or laboratory signs of intolerance.\n* Previous history of cancer, other than basal cell or stage 1 squamous cell carcinoma, that has not been in remission for at least 5 years prior to the first dose of study medication.\n* History of acute or chronic metabolic acidosis, including diabetic ketoacidosis with or without coma.\n* Any disease or condition at Screening or Randomization that would compromise safety, might affect life expectancy, or make it difficult to successfully manage and follow the subject according to the protocol.\n* Currently participating in another investigational study or has participated in an investigational study within 30 days prior to randomization.\n* Is required to take or continues taking any disallowed medication, prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:\n\n  * Antidiabetic medications other than study medication\n  * Chronically used oral or parenteral glucocorticoids\n  * Niacin greater than 200 mg per day, including niacin-containing products such as Advicor\n  * Chronically used steroid-joint injections","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Glycosylated Hemoglobin","description":"The change between the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at final visit or week 24 and Glycosylated Hemoglobin collected at baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.83","spread":"0.122"},{"groupId":"OG001","value":"-0.96","spread":"0.131"},{"groupId":"OG002","value":"-0.99","spread":"0.120"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose","description":"The change between the value of Fasting Plasma Glucose collected at final visit or week 24 and Fasting Plasma Glucose collected at baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-39.9","spread":"3.48"},{"groupId":"OG001","value":"-22.2","spread":"3.67"},{"groupId":"OG002","value":"-24.8","spread":"3.42"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Insulin","description":"The change between the Fasting Insulin value collected at final visit or week 24 and Fasting Insulin collected at baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.91","spread":"0.736"},{"groupId":"OG001","value":"-3.18","spread":"0.812"},{"groupId":"OG002","value":"-0.98","spread":"0.722"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Homeostasis Model Assessment - Insulin Resistance","description":"The change between Homeostasis Model Assessment of Insulin Resistance collected at final visit or week 24 and Homeostasis Model Assessment of Insulin Resistance collected at baseline. Homeostasis Model Assessment measures insulin resistance, calculated by insulin times glucose, divided by a constant (22.5).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.704","spread":"0.4274"},{"groupId":"OG001","value":"-2.075","spread":"0.4586"},{"groupId":"OG002","value":"-1.085","spread":"0.4123"}]}]}]},{"type":"SECONDARY","title":"Median Percent Change From Baseline in High Sensitivity C-reactive Protein","description":"Measurement for High Sensitivity C-reactive Protein was collected at final visit or week 24 and at baseline. Percent change from baseline is calculated as: \\[(Week 24 - baseline levels)/baseline\\]\\*100","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-36.7","spread":"4.6719"},{"groupId":"OG001","value":"-34.0","spread":"8.1275"},{"groupId":"OG002","value":"-26.2","spread":"12.5526"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Adiponectin","description":"The change between Adiponectin collected at final visit or week 24 and Adiponectin collected at baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.8","spread":"0.55"},{"groupId":"OG001","value":"9.2","spread":"0.61"},{"groupId":"OG002","value":"-0.3","spread":"0.55"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Total Cholesterol","description":"The change between Total Cholesterol collected at final visit or week 24 and Total Cholesterol collected at baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.06","spread":"1.183"},{"groupId":"OG001","value":"4.79","spread":"1.271"},{"groupId":"OG002","value":"-2.72","spread":"1.169"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Low-Density Lipoprotein Cholesterol","description":"The change between Low-Density Lipoprotein Cholesterol collected at final visit or week 24 and Low-Density Lipoprotein Cholesterol collected at baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.19","spread":"2.015"},{"groupId":"OG001","value":"6.08","spread":"2.175"},{"groupId":"OG002","value":"-1.37","spread":"1.998"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in High-Density Lipoprotein Cholesterol","description":"The change between High-Density Lipoprotein Cholesterol collected at final visit or week 24 and High-Density Lipoprotein Cholesterol collected at baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.20","spread":"1.440"},{"groupId":"OG001","value":"9.88","spread":"1.552"},{"groupId":"OG002","value":"6.09","spread":"1.426"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Triglycerides","description":"The change between Triglycerides collected at final visit or week 24 and Triglycerides collected at baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.95","spread":"2.901"},{"groupId":"OG001","value":"-5.54","spread":"3.107"},{"groupId":"OG002","value":"-1.78","spread":"2.871"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean Low Density Lipoprotein Particle Concentration","description":"The change between Low Density Lipoprotein particle concentration collected at final visit or week 24 and Low Density Lipoprotein particle concentration collected at baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-240.6","spread":"23.50"},{"groupId":"OG001","value":"-217.2","spread":"25.40"},{"groupId":"OG002","value":"-176.4","spread":"23.36"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean Low Density Lipoprotein Particle Size","description":"The change between Low Density Lipoprotein collected at final visit or week 24 and Low Density Lipoprotein collected at baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.55","spread":"0.049"},{"groupId":"OG001","value":"0.6","spread":"0.053"},{"groupId":"OG002","value":"0.2","spread":"0.049"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Large Low Density Lipoprotein (L3) Concentration","description":"The change between Large Low Density Lipoprotein collected at final visit or week 24 and Large Low Density Lipoprotein collected at baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.0","spread":"12.53"},{"groupId":"OG001","value":"115.7","spread":"13.52"},{"groupId":"OG002","value":"18.4","spread":"12.46"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Intermediate-Density Low Density Lipoprotein Concentration","description":"The change between Intermediate-Density Low Density Lipoprotein collected at final visit or week 24 and Intermediate-Density Low Density Lipoprotein collected at baseline","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.3","spread":"3.39"},{"groupId":"OG001","value":"-11.0","spread":"3.66"},{"groupId":"OG002","value":"-17.3","spread":"3.37"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Medium-Small Low Density Lipoprotein Concentration","description":"The change between Medium-Small Low Density Lipoprotein collected at final visit or week 24 and Medium-Small Low Density Lipoprotein collected at baseline","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-63.8","spread":"5.95"},{"groupId":"OG001","value":"-66.0","spread":"6.43"},{"groupId":"OG002","value":"-35.3","spread":"5.92"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Small Low Density Lipoprotein Concentration","description":"The change between Small Low Density Lipoprotein collected at final visit or week 24 and Small Low Density Lipoprotein collected at baseline","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-319.3","spread":"28.06"},{"groupId":"OG001","value":"-321.3","spread":"30.34"},{"groupId":"OG002","value":"-179.0","spread":"27.91"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Very Small Low Density Lipoprotein Concentration","description":"The change between Very Small Low Density Lipoprotein collected at final visit or week 24 and Very Small Low Density Lipoprotein collected at baseline","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-255.5","spread":"22.37"},{"groupId":"OG001","value":"-255.2","spread":"24.18"},{"groupId":"OG002","value":"-143.8","spread":"22.25"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean High Density Lipoprotein Particle Concentration","description":"The change between High Density Lipoprotein collected at final visit or week 24 and High Density Lipoprotein collected at baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.28","spread":"0.271"},{"groupId":"OG001","value":"-0.80","spread":"0.293"},{"groupId":"OG002","value":"0.62","spread":"0.269"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean High Density Lipoprotein Particle Size","description":"The change between High Density Lipoprotein collected at final visit or week 24 and High Density Lipoprotein collected at baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.15","spread":"0.021"},{"groupId":"OG001","value":"0.19","spread":"0.022"},{"groupId":"OG002","value":"0.11","spread":"0.021"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Large High Density Lipoprotein (H4+H5) Concentration","description":"The change between Large High Density Lipoprotein collected at final visit or week 24 and Large High Density Lipoprotein collected at baseline","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.70","spread":"1.80"},{"groupId":"OG001","value":"1.02","spread":"0.194"},{"groupId":"OG002","value":"0.52","spread":"0.179"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Intermediate-Medium High Density Lipoprotein (H3) Concentration","description":"The change between Intermediate-Medium High Density Lipoprotein collected at final visit or week 24 and Intermediate-Medium High Density Lipoprotein collected at baseline","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.34","spread":"0.285"},{"groupId":"OG001","value":"1.62","spread":"0.308"},{"groupId":"OG002","value":"-0.09","spread":"0.283"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Small High Density Lipoprotein (H1+H2) Concentration","description":"The change between Small High Density Lipoprotein collected at final visit or week 24 and Small High Density Lipoprotein collected at baseline","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.78","spread":"0.349"},{"groupId":"OG001","value":"-3.41","spread":"0.377"},{"groupId":"OG002","value":"0.19","spread":"0.347"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean Very Low Density Lipoprotein Particle Concentration","description":"The change between Very Low Density Lipoprotein collected at final visit or week 24 and Very Low Density Lipoprotein collected at baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.78","spread":"2.204"},{"groupId":"OG001","value":"0.98","spread":"2.381"},{"groupId":"OG002","value":"-11.30","spread":"2.191"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean Very Low Density Lipoprotein Particle Size","description":"The change between Very Low Density Lipoprotein collected at final visit or week 24 and Very Low Density Lipoprotein collected at baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.64","spread":"0.616"},{"groupId":"OG001","value":"-3.79","spread":"0.666"},{"groupId":"OG002","value":"-0.20","spread":"0.612"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Large-Chylomicrons Very Low Density Lipoprotein Concentration","description":"The change between Large-Chylomicrons Very Low Density Lipoprotein collected at final visit or week 24 and Large-Chylomicrons Very Low Density Lipoprotein collected at baseline","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.71","spread":"0.351"},{"groupId":"OG001","value":"-1.97","spread":"0.379"},{"groupId":"OG002","value":"-1.96","spread":"0.349"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Medium-Intermediate Very Low Density Lipoprotein (V3+V4) Concentration","description":"The change between Medium-Intermediate Very Low Density Lipoprotein collected at final visit or week 24 and Medium-Intermediate Very Low Density Lipoprotein collected at baseline","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.07","spread":"1.434"},{"groupId":"OG001","value":"-3.01","spread":"1.550"},{"groupId":"OG002","value":"-6.48","spread":"1.426"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Small Very Low Density Lipoprotein (V1+V2) Concentration","description":"The change between Small Very Low Density Lipoprotein collected at final visit or week 24 and Small Very Low Density Lipoprotein collected at baseline","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.05","spread":"1.249"},{"groupId":"OG001","value":"5.9","spread":"1.350"},{"groupId":"OG002","value":"-2.86","spread":"1.239"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":201},"commonTop":["Diarrhoea","Headache","Pharyngitis","Urinary tract infection","Back pain"]}}}